<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02937181</url>
  </required_header>
  <id_info>
    <org_study_id>TEF-IT-40B</org_study_id>
    <nct_id>NCT02937181</nct_id>
  </id_info>
  <brief_title>Antibiotic Prophylaxis in Open Fractures</brief_title>
  <official_title>Antibiotic Prophylaxis With Ceftaroline for Type II and II Open Fractures: a Phase 4, Open-label, Prospective Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olayemi Osiyemi MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Triple O Research Institute PA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective look at antibiotic prophylaxis with Ceftaroline in patients with type II and III
      open fractures
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Determine if antibiotic prophylaxis with Ceftaroline in patients with type II and III open
      fractures is a safe and effective alternative to standard combination therapy
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of fracture site infection at 30 days between ceftaroline and historical hospital rate</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute kidney injury</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Identify bacteria associated with the infections</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>identify the number of infections associated with sites other than fracture site</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Open Fractures</condition>
  <arm_group>
    <arm_group_label>open fractures type II and III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every patients will receive Ceftaroline in an open label, single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftaroline</intervention_name>
    <description>IV Ceftaroline will be given for 72 hours</description>
    <arm_group_label>open fractures type II and III</arm_group_label>
    <other_name>Teflaro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female &gt;= 18 years old

          -  complete an informed consent

          -  patients are diagnosed with a type II or III open fracture

        Exclusion Criteria:

          -  allergy to beta-lactam antibiotics prior to screening

          -  prior to enrollment: patients received 3 or more doses of antibiotic prophylaxis

          -  pregnant female

          -  inability to provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olayemi Osiyemi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Triple O Research Institute PA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Glickman</last_name>
    <phone>561-855-7871</phone>
    <email>pglickman@tripleoresearch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olayemi Osiyemi, MD</last_name>
    <phone>561-855-7871</phone>
    <email>drtripleo@tripleoresearch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Triple O Research Institute PA</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Triple O Research Institute PA</investigator_affiliation>
    <investigator_full_name>Olayemi Osiyemi MD</investigator_full_name>
    <investigator_title>President/</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Fractures, Open</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>no personal data, identifier and the data are made available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

